Lantheus Medical Imaging has started a Phase I trial on LMI1195, a fluorine-18 small-molecule PET imaging agent used to determine cardiac neuronal function. The study aims to evaluate the safety and tolerability of the tracer, as well as assess the agent's dosimetry and PET imaging parameters and quality.

Related Summaries